Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | NQO1 | P15559 | 1/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19464647 | 0.88 | ACACB (0.34) | ACACBMEN1KMT2ACYP1A2 | |
| SCHEMBL19987499 | 0.85 | NR1I2 (0.36) | ACACB | |
| SCHEMBL19987480 | 0.83 | ACACB (0.35) | ACACB | |
| SCHEMBL19232025 | 0.83 | ACACB (0.35) | ACACBMEN1KMT2ACYP1A2NQO1 | |
| SCHEMBL19987502 | 0.83 | TUBB4A (0.38) | — | |
| SCHEMBL24804934 | 0.82 | NR1I2 (0.43) | ACACB | |
| SCHEMBL19464598 | 0.82 | NR1I2 (0.43) | ACACB | |
| SCHEMBL19231981 | 0.81 | ACACB (0.39) | ACACBMEN1KMT2ACYP1A2NQO1 | |
| SCHEMBL12413771 | 0.80 | ACACB (0.41) | ACACBMEN1KMT2ACYP1A2NQO1 | |
| SCHEMBL19987479 | 0.79 | ACACB (0.34) | ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-10167254-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-22 | — | — | US | disclosed |
| US-9790169-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170231999-A1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167254-B2 | IDO inhibitors | IDO1, IDO2, INMT | ACACB 411/4885MEN1 2981/4885KMT2A 461/4885 |
| US-20170231999-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | ACACB 411/4885MEN1 2981/4885KMT2A 461/4885 |
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | ACACB 347/4885MEN1 2234/4885KMT2A 400/4885 |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | ACACB 347/4885MEN1 2234/4885KMT2A 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.